Compare Moderna, Inc. (MRNA) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Newmont Corporation — how do they compare? Moderna, Inc. trades at $136.5 (market cap $54.14B), while Newmont Corporation trades at $127.09 (market cap $135.62B). The key difference: Newmont Corporation is far larger — about 2.5× Moderna, Inc.'s market cap, and Newmont Corporation pays a 0.81% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NEM | |
|---|---|---|
Market Cap | $54.14B | $135.62B |
Sector | Health | Basic Materials |
52-Week High | $174.38 | $135.14 |
52-Week Low | $22.36 | $78.32 |
Enterprise Value | $50.29B | $132.21B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
NEM trades at $127.09, down 0.78% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $22.67B in 2025, with net income surging to $7.09B, and Q2 2026 EPS beat expectations at $2.10. Analyst consensus is strongly bullish with a $134.63 price target, supported by record free cash flow and institutional buying.
Outlook remains positive given earnings beats and gold's safe-haven appeal, but production challenges and cost pressures pose risks. The stock offers growth from operational strength and shareholder returns, yet investors face volatility from commodity prices and execution hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
